阿巴洛帕肽对绝经后骨质疏松症女性前臂骨密度及腕部骨折风险的影响
ACTIVE 3期研究的探索性分析评估阿巴洛帕肽对比安慰剂和特立帕肽对前臂骨密度及腕部骨折风险的影响。18个月时,阿巴洛帕肽较安慰剂和特立帕肽均增加超远端桡骨骨密度,1/3桡骨骨密度丢失少于特立帕肽;腕部骨折发生率在阿巴洛帕肽组数值上低于特立帕肽组(HR=0.43)和安慰剂组(HR=0.49),但均未达统计学显著。
要点
- 18个月时超远端桡骨骨密度变化:阿巴洛帕肽较安慰剂高2.25个百分点(95%CI 1.38,3.12,p<0.001),较特立帕肽高1.54个百分点(95%CI 0.64,2.45,p<0.001)。
- 1/3桡骨骨密度丢失:阿巴洛帕肽与安慰剂相似(-0.42,95%CI -1.03,0.20,p=0.19),特立帕肽丢失超过安慰剂(-1.66%,95%CI -2.27,-1.06,p<0.001),阿巴洛帕肽组丢失少于特立帕肽组(组间差异1.22%,95%CI 0.57,1.87,p<0.001)。
- 腕部骨折发生率阿巴洛帕肽组数值上低于特立帕肽组(HR=0.43,95%CI 0.18,1.03,p=0.052)和安慰剂组(HR=0.49,95%CI 0.20,1.19,p=0.11),均未达统计学显著。
核心结论
- 与特立帕肽相比,阿巴洛帕肽增加超远端桡骨(主要为小梁骨)骨密度,并在1/3桡骨(主要为皮质骨)骨密度降低程度上较轻,可能促成了阿巴洛帕肽组观察到的数值上较低的腕部骨折发生率。
研究设计与样本
- ACTIVE 3期研究的探索性分析,前臂骨密度在982名女性亚组中采用双能X线吸收法测量,三组分布均匀;腕部骨折在总队列(N=2463)中确定。
主要发现
- 18个月后,超远端桡骨骨密度自基线变化:阿巴洛帕肽较安慰剂高2.25个百分点(95%CI 1.38,3.12,p<0.001),较特立帕肽高1.54个百分点(95%CI 0.64,2.45,p<0.001)。
- 18个月时,1/3桡骨骨密度较基线丢失:阿巴洛帕肽与安慰剂相似(-0.42,95%CI -1.03,0.20,p=0.19);特立帕肽丢失超过安慰剂(-1.66%,95%CI -2.27,-1.06,p<0.001);阿巴洛帕肽组丢失少于特立帕肽组(组间差异1.22%,95%CI 0.57,1.87,p<0.001)。
- 腕部骨折发生率:阿巴洛帕肽组数值上低于特立帕肽组(HR=0.43,95%CI 0.18,1.03,p=0.052)和安慰剂组(HR=0.49,95%CI 0.20,1.19,p=0.11),均未达统计学显著。
关键数值与推荐
- 超远端桡骨骨密度变化组间差异:阿巴洛帕肽 vs 安慰剂 2.25个百分点(95%CI 1.38,3.12,p<0.001);阿巴洛帕肽 vs 特立帕肽 1.54个百分点(95%CI 0.64,2.45,p<0.001)。
- 1/3桡骨骨密度变化:阿巴洛帕肽 vs 安慰剂 -0.42(95%CI -1.03,0.20,p=0.19);特立帕肽 vs 安慰剂 -1.66%(95%CI -2.27,-1.06,p<0.001);阿巴洛帕肽 vs 特立帕肽组间差异1.22%(95%CI 0.57,1.87,p<0.001)。
- 腕部骨折风险:阿巴洛帕肽 vs 特立帕肽 HR=0.43(95%CI 0.18,1.03,p=0.052);阿巴洛帕肽 vs 安慰剂 HR=0.49(95%CI 0.20,1.19,p=0.11)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus placebo and teriparatide on forearm bone mineral density (BMD) and risk of wrist fracture. METHODS: Forearm BMD was measured by dual energy X-ray absorptiometry in a subset of 982 women from ACTIVE, evenly distributed across the three treatment groups. Wrist fractures were ascertained in the total cohort (N = 2463). RESULTS: After 18 months, ultradistal radius BMD changes from baseline were 2.25 percentage points greater for abaloparatide compared with placebo (95% confidence interval (CI) 1.38, 3.12, p < 0.001) and 1.54 percentage points greater for abaloparatide compared with teriparatide (95% CI 0.64, 2.45, p < 0.001). At 18 months, 1/3 radius BMD losses (versus baseline) were similar for abaloparatide compared with placebo (-0.42; 95% CI -1.03, 0.20; p = 0.19) but losses with teriparatide exceeded those of placebo (-1.66%; 95% CI -2.27, -1.06; p < 0.001). The decline with abaloparatide was less than that seen with teriparatide (group difference 1.22%; 95% CI 0.57, 1.87; p < 0.001). The radius BMD findings, at both ultradistal and 1/3 sites, are consistent with the numerically lower incidence of wrist fractures observed in women treated with abaloparatide compared with teriparatide (HR = 0.43; 95% CI 0.18, 1.03; p = 0.052) and placebo (HR = 0.49, 95% CI 0.20, 1.19, p = 0.11). CONCLUSIONS: Compared with teriparatide, abaloparatide increased BMD at the ultradistal radius (primarily trabecular bone) and decreased BMD to a lesser extent at the 1/3 radius (primarily cortical bone), likely contributing to the numerically lower wrist fracture incidence observed with abaloparatide.
引用
- Watts NB, Hattersley G, Fitzpatrick LA, et al. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2019. PMID: 30899994. doi:10.1007/s00198-019-04890-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。